Antimicrobial-resistant infections
Feature
Antibiotic resistance: Personal responsibility in somewhat short supply
Many primary care physicians are not making the connection between themselves and the larger issue.
Article
ID dermatology: Advancements, but new challenges, over 50 years
One of the biggest wins for ID dermatology over the last 5 decades has been herpes. It started with the approval of acyclovir in 1981.
Latest News
Antibiotic resistance rises among pneumococcus strains in kids
Evolution is at work in the emergence of vaccine-resistance serotypes not included in the PCV-13 vaccine.
Conference Coverage
Children with resistant UTIs unexpectedly may respond to discordant antibiotics
A low rate of care escalation and high rate of clinical improvement suggest this may be a reasonable approach until urine culture sensitivities...
Article
FDA approves cefiderocol for multidrug-resistant, complicated urinary tract infections
The approval is for patients with limited or no alternative treatment options and includes a warning of Fetroja’s higher all-cause mortality rate...
News
CDC releases update of 2013 Antibiotic Resistance Threats Report
The report includes the hopeful news that there were 42 new antibiotics in development as of June 2019.
Conference Coverage
Rifabutin-based triple therapy for H. pylori gets high marks
SAN ANTONIO – This is the first new Helicobacter pylori eradication agent to be approved by the Food and Drug Administration in 22 years...
Conference Coverage
IDWeek examined hot topics in the clinical treatment of infectious diseases
WASHINGTON –
Video
Oral beta-lactams provide noninferior postdischarge pyelonephritis treatment
WASHINGTON – Beta-lactams were noninferior to fluoroquinolones or trimethoprim-...
Conference Coverage
Hospital slashes S. aureus vancomycin resistance
LJUBLJANA, SLOVENIA – Staphylococcus aureus resistance to vancomycin is not a one-way street ending in a cliff plunge.
News
FDA approves Recarbrio for cUTI, cIAI treatment in adults
Recarbrio is a three-drug combined injection of imipenem/cilastatin and relebactam.